After substantial slowing in year-over-year growth across 8 markets that BDSA covers in November, cannabis sales growth bounced back in December. The January data suggests a mixed picture of growth trends, but one conclusion is quite apparent: Flower continues to be in exceptionally strong demand, signaling that the legal markets continue to convert consumers of the illicit market. In this review, we will look at the markets one-by-one, beginning with the more mature Western markets and then concluding with the newer Eastern markets.
BDSA provides coverage for Arizona, California, Colorado, Nevada and Oregon. In January, growth ranged from 19% in Nevada to 48% in Oregon compared to a year ago.
During January, Arizona medical cannabis sales totaled $87.7 million, down 4% from December and up 23.9% from a year ago. This rate of growth is down from 30.3% in December and 28.4% in November and represents the slowest growth in more than a year. In contrast to most of the other states, flower grew only inline with overall sales, increasing 22.5%, with concentrates expanding 29.6%. Pre-rolls, a relatively small category, grew by 83.1% compared to a year ago.
California cannabis sales expanded 28.6% in January to $243.5 million, which was an increase from 25% in December and 24% in November. The sequential decline was 0.4%. Flower sales,which were 35.6% of overall sales, continued to lead growth, expanding 44% during the month, with pre-roll demand strong as well. The pre-roll category, which is more than 10% of the market, grew almost 36% compared to a year ago.
Colorado, the first state to legalize for adult-use, continues to grow at a fast pace, with January sales of $140.9 million increasing 35.5% compared to a year ago as they fell 1.7% sequentially. The growth almost matched the highest level